Aug 10, 2023 4:30pm EDT Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Jun 03, 2023 4:00pm EDT Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1
May 15, 2023 8:00am EDT Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Apr 27, 2023 4:30pm EDT Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
Apr 18, 2023 1:30pm EDT Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
